NASDAQ:GWPHGW Pharmaceuticals PLC- Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GW Pharmaceuticals PLC- Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$120.20MA: $129.06▼$139.5452-Week Range N/AVolume2.38 million shsAverage Volume302,630 shsMarket Capitalization$4.10 billionP/E RatioN/ADividend YieldN/ABeta1.92 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingGW Pharmaceuticals PLC- has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $179.50, GW Pharmaceuticals PLC- has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageGW Pharmaceuticals PLC- has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesGW Pharmaceuticals PLC- has received 806 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGW Pharmaceuticals PLC- has received 532 “underperform” votes. (Add your “underperform” vote.)Community SentimentGW Pharmaceuticals PLC- has received 60.24% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote “Outperform” if you believe GWPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGW Pharmaceuticals PLC- does not currently pay a dividend.Dividend GrowthGW Pharmaceuticals PLC- does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GW Pharmaceuticals PLC- insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,867,272.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of GW Pharmaceuticals PLC- is held by insiders.Percentage Held by Institutions81.34% of the stock of GW Pharmaceuticals PLC- is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GW Pharmaceuticals PLC- are expected to grow in the coming year, from ($2.01) to $3.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GW Pharmaceuticals PLC- is -59.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GW Pharmaceuticals PLC- is -59.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.82 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GWPH Previous Symbol CUSIPN/A CIK1351288 Webwww.gwpharm.com Phone44-12-2326-6800Debt Debt-to-Equity Ratio0.01 Current Ratio6.50 Quick Ratio5.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$311.33 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow18,483.28 Book Value$23.48 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.24) Net Income$-9,020,000.00 Net Margins-12.56% Return on Equity-7.71% Return on Assets-6.44%Miscellaneous Employees791 Outstanding Shares31,050,000Market Cap$4.10 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable 30 days | 90 days | 365 days | Advanced Chart Receive GWPH News and Ratings via Email Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter. GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of GW Pharmaceuticals PLC-? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-. When is GW Pharmaceuticals PLC-'s next earnings date? GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for GW Pharmaceuticals PLC-. How were GW Pharmaceuticals PLC-'s earnings last quarter? GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The biopharmaceutical company earned $121.30 million during the quarter, compared to analysts' expectations of $94.57 million. GW Pharmaceuticals PLC- had a negative return on equity of 7.71% and a negative net margin of 12.56%. The company's quarterly revenue was up 68.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.21 EPS. View GW Pharmaceuticals PLC-'s earnings history. What price target have analysts set for GWPH? 10 brokers have issued 12-month target prices for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $128.00 to $275.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $179.50 in the next year. View analysts' price targets for GW Pharmaceuticals PLC-. Has GW Pharmaceuticals PLC- been receiving favorable news coverage? News stories about GWPH stock have trended very positive on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a news impact score of 4.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about GW Pharmaceuticals PLC-. Who are some of GW Pharmaceuticals PLC-'s key competitors? Some companies that are related to GW Pharmaceuticals PLC- include Horizon Therapeutics (HZNP), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ) and Perrigo (PRGO). View all competitors. What other stocks do shareholders of GW Pharmaceuticals PLC- own? Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA), Walt Disney (DIS), Aurora Cannabis (ACB), Intel (INTC) and Gilead Sciences (GILD). Who are GW Pharmaceuticals PLC-'s key executives? GW Pharmaceuticals PLC-'s management team includes the following people: Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)Mr. Justin D. Gover, CEO & Exec. Director (Age 48)Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61) What is GW Pharmaceuticals PLC-'s stock symbol? GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH." Who are GW Pharmaceuticals PLC-'s major shareholders? GW Pharmaceuticals PLC-'s stock is owned by a variety of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (1.85%), M&G Investment Management Ltd. (1.72%), Redwood Investments LLC (0.42%), Candriam Luxembourg S.C.A. (0.39%), Hardman Johnston Global Advisors LLC (0.20%) and GW&K Investment Management LLC (0.18%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View institutional ownership trends for GW Pharmaceuticals PLC-. Which major investors are selling GW Pharmaceuticals PLC- stock? GWPH stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Victory Capital Management Inc., GW&K Investment Management LLC, Janney Montgomery Scott LLC, Cambridge Investment Research Advisors Inc., Rathbone Brothers plc, Gables Capital Management Inc., and Creative Planning. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Cabot Brown, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello, and Volker Knappertz. View insider buying and selling activity for GW Pharmaceuticals PLC-. Which major investors are buying GW Pharmaceuticals PLC- stock? GWPH stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., RMB Capital Management LLC, Financial Counselors Inc., Trexquant Investment LP, Hardman Johnston Global Advisors LLC, Quantitative Systematic Strategies LLC, Leap Investments LP, and Altfest L J & Co. Inc.. View insider buying and selling activity for GW Pharmaceuticals PLC-. How do I buy shares of GW Pharmaceuticals PLC-? Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How big of a company is GW Pharmaceuticals PLC-? GW Pharmaceuticals PLC- has a market capitalization of $0.00 and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe. What is GW Pharmaceuticals PLC-'s official website? The official website for GW Pharmaceuticals PLC- is www.gwpharm.com. How can I contact GW Pharmaceuticals PLC-? GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
